AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Coimbatore's Nalam Kaakkum Stalin Medical Camps Reach 8,095 Beneficiaries with Comprehensive Healthcare Services
ByAinvest
Thursday, Sep 4, 2025 10:28 am ET1min read
The Nalam Kaakkum Stalin scheme has provided health check-ups to over 8,000 people in Coimbatore district. Medical camps were held in four locations, offering services in various specialties such as ENT, ophthalmology, and cardiology. The camps operated every Saturday and provided consultations, minor procedures, diagnostics, and screenings for blood pressure, blood sugar, and cancer detection. Participants received records for follow-up care.
Mineralys Therapeutics' shares surged by approximately 85% following the release of full results from AstraZeneca's Phase 3 trial for baxdrostat, a blood pressure medicine. The 12-week BaxHTN trial demonstrated significant reductions in systolic blood pressure (SBP) compared to placebo, with the 2 mg baxdrostat dose showing a placebo-adjusted reduction of 9.8 mmHg [1]. The trial, which enrolled 796 patients, showed that baxdrostat 2 mg lowered SBP by 15.7 mmHg (9.8 mmHg placebo-adjusted) from baseline, and was generally well tolerated. The results were presented at the European Society of Cardiology Congress 2025 and published in the New England Journal of Medicine [1].Mineralys Therapeutics is developing lorundrostat, a similar drug to baxdrostat, for the treatment of resistant hypertension. The positive results from the BaxHTN trial suggest that lorundrostat could also be effective in managing hard-to-control hypertension, potentially opening new avenues for Mineralys' lead asset. AstraZeneca's positive trial results and the potential for lorundrostat to follow suit have bolstered investor confidence in Mineralys Therapeutics. The company's shares have seen a substantial increase, reflecting the market's optimism about the potential of lorundrostat in the treatment of resistant hypertension.
References:
[1] https://www.astrazeneca.com/media-centre/press-releases/2025/baxdrostat-demonstrated-statistically-significant-clinically-meaningful-reduction-sbp-patients-hard-control-hypertension-baxhtn-phase-iii-trial.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet